JLHL

Concall Schedule Concall Date: Monday, 26th October 2026 Concall Time: 10:00 AM IST

- Trading window closed with effect from October 01, 2026. - Reopens 48 hours after declaration of financial results for quarter and half year ending September 30, 2026. - Closure applies to all Designated Persons and their immediate relatives.

- Investor Conference Schedule - Concall Date: 28th September 2026 - Concall Time: 1:00 pm to 5:00 pm

- Q1 FY27 Consolidated performance: Total income ₹411 Cr, EBITDA ₹79.3 Cr (19.3% margin), PAT ₹37.5 Cr. - Dombivli Hospital: Completed first full quarter, contributed ₹9.5 Cr EBITDA drag as anticipated, with occupancy at 25-30%. Breakeven is still expected in 1.5-2 years, with oncology & radiation services launching by year-end. - Indore unit: Experienced lower Q1 EBITDA margin (12%) due to new hires for anticipated growth and is expected to grow faster than other units. - ARPOB grew 10% YoY driven by case mix improvement and contract renegotiations. - Net Debt: Company maintains effectively 0 net debt, with ~₹500 Cr debt and ~₹500 Cr cash. - Strategic Initiative: Acquired an IV fluid manufacturing plant for ₹35-40 Cr for backward integration to manage costs and improve margins. - Future Outlook: Focus on delivering 3 announced projects within the next 5 years, targeting Western India due to strong demand-supply gap in organized healthcare. - Pledged Shares: Clarified that the apparent increase in pledged shares was due to a 5x stock split, not new pledges, and was a non-promoter pledge; filing has been corrected.

- Audio link for Q1 FY27 Analyst/Investor Conference Call, held on August 3, 2026, is now available on the company website. - Link: jupiterhospital.com/wp-content/uploads/2026/08/earning-call-audio-recording-quarter1.mp3

- The Board of Directors on July 31, 2026, authorized Mr. Harshad Purani (CFO), in addition to Dr. Ankit Thakker (MD & CEO), for determining the materiality of events/information. - Ms. Suma Upparatti (Company Secretary & Compliance Officer) is authorized for disclosure to the Stock Exchanges.

- Consolidated Revenue ₹4,109.83Mn vs ₹3,529.53Mn (▲16.44% YoY) - EBITDA ₹792.69Mn vs ₹784.20Mn (▲1.08% YoY) - PAT ₹375.12Mn vs ₹439.45Mn (▼14.64% YoY) - EBITDA Margin 19.29% vs 22.22% (▼293bps) - Board approved the appointment of Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel. - A subsidiary acquired 100% equity share capital of Sulcus Private Limited for ₹3.78 crore, making it a step-down subsidiary.

- Consolidated Revenue ₹410.98 Cr vs ₹352.95 Cr (▲16.44% YoY) - EBITDA ₹79.27 Cr vs ₹78.42 Cr (▲1.08% YoY) - PAT ₹37.51 Cr vs ₹43.95 Cr (▼14.64% YoY) - EBITDA Margin 19.29% vs 22.22% (▼293bps) - Board approved the appointment of Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel. - Acquired 100% equity share capital of Sulcus Private Limited for ₹3.78 crore, making it a step-down wholly owned subsidiary.

- Consolidated Revenue ₹410.98 Cr vs ₹352.95 Cr (▲16.44% YoY) - EBITDA ₹79.27 Cr vs ₹78.42 Cr (▲1.08% YoY) - PAT ₹37.49 Cr vs ₹43.89 Cr (▼14.60% YoY) - EBITDA Margin 19.29% vs 22.22% (▼293bps) - Board approved the appointment of Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel. - Company acquired 100% of the equity share capital of Sulcus Private Limited for ₹3.78 crore, making it a wholly-owned step-down subsidiary.